Bleeding After Elective Interventional Endoscopic Procedures in a Large Cohort of Patients With Cirrhosis

Shanker Kundumadam, MBBS1, Parkpoom Phatharacharukul, MD1, Kathryn Reinhart, BS1, Andrew Yousef, MD2, Hani Shamseddine, MD1, Francis Pike, PhD3, Kavish R. Patidar, DO1, Mark Gromski, MD1, Naga Chalasani, MD1 and Eric S. Orman, MD, MSCR1

INTRODUCTION: Elective therapeutic endoscopy is an important component of care of cirrhotic patients, but there are concerns regarding the risk of bleeding. This study examined the incidence, risk factors, and outcomes of bleeding after endoscopic variceal ligation (EVL), colonoscopic polypectomy, and endoscopic retrograde cholangiopancreatography with sphincterotomy in cirrhotic patients.

METHODS: A cohort study of patients with cirrhosis who underwent the above procedures at a single center between 2012 and 2014 was performed. Patients with active bleeding at the time of procedure were excluded. Patients were followed for 30 days to assess for postprocedural bleeding and for 90 days for mortality.

RESULTS: A total of 1,324 procedures were performed in 857 patients (886 upper endoscopies, 358 colonoscopies, and 80 endoscopic retrograde cholangiopancreatographies). After EVL, bleeding occurred in 2.8%; after polypectomy, bleeding occurred in 2.0%; and after sphincterotomy, bleeding occurred in 3.8%. Independent predictors of bleeding after EVL and polypectomy included younger age and lower hemoglobin. For EVL, bleeding was also associated with infection and model for end-stage liver disease-Na. International normalized ratio was associated with bleeding in univariate analysis only, and platelet count was not associated with bleeding in any procedure. Bleeding after EVL was associated with 29% 90-day mortality, and bleeding after polypectomy was associated with 14% mortality. Of the 3 patients with post sphincterotomy bleeding, none were outliers regarding their baseline characteristics.

DISCUSSION: In patients with cirrhosis, bleeding occurs infrequently after elective therapeutic endoscopy and is associated with younger age, lower hemoglobin, and high mortality. Consideration of these risk factors may guide appropriate timing and preprocedural management to optimize outcomes.

Clinical and Translational Gastroenterology 2020;11:e00288. https://doi.org/10.14309/ctg.0000000000000288

INTRODUCTION
Patients with cirrhosis have an increased risk of bleeding, in part, because of various hemostatic abnormalities (1). Portal hypertension-induced hypersplenism and reduced hepatic synthesis of thrombopoietin can result in thrombocytopenia. In addition, the reduced hepatic synthesis of coagulation factors can lead to impaired coagulation. These defects can increase patients’ risk of spontaneous bleeding; they can also predispose patients to bleeding after invasive procedures (2,3). Several invasive endoscopic procedures are frequently required in the routine care of patients with cirrhosis. Upper endoscopy is used to screen patients for gastroesophageal varices, which are highly prevalent in cirrhosis (4). Colonoscopy is often performed for colorectal cancer screening; most patients with cirrhosis are older than 50 years (the age at which screening is generally recommended), and cirrhosis is an independent risk factor for colonic adenomas (5). Finally, endoscopic retrograde cholangiopancreatography (ERCP) is often needed to assess patients with biliary disease-associated cirrhosis (e.g., primary sclerosing cholangitis), and ERCP may be needed in cases of diagnostic uncertainty when patients with liver disease have cholestasis.

During these procedures, several interventions are considered to have a high associated bleeding risk, including endoscopic variceal ligation (EVL), colonoscopic polypectomy, and biliary...
sphincterotomy (6). The risk of bleeding after these procedures in patients with cirrhosis has been examined in several studies. However, these studies have been limited by small sample sizes (7–11), lack of detailed risk factor assessment for cirrhosis specifically (12), inclusion of noninterventional procedures (e.g., ERCP without sphincterotomy) (13,14), inclusion of emergent procedures performed for active bleeding (15–18), and inclusion of nonendoscopic procedures (19–21). Understanding the bleeding risk in purely elective therapeutic procedures is important because it is in this group that careful decisions can be made regarding procedural timing, preprocedural medication management, and bleeding prophylaxis. These decisions can also be extended to diagnostic procedures with the potential for therapeutic intervention.

To better understand the risk of bleeding after therapeutic endoscopy in this important population, a large cohort of patients with cirrhosis at a tertiary liver center was examined. The primary goals were to examine (i) incidence, (ii) risk factors, and (iii) outcomes of bleeding after therapeutic endoscopy.

**METHODS**

**Patients and study design**

This was a retrospective cohort study of all patients with cirrhosis who had any of the following procedures at a large tertiary care teaching hospital between January 1, 2012, and December 31, 2014: EVL, colonoscopy with polypectomy, and ERCP with biliary or pancreatic sphincterotomy. Procedures performed after 2014 were not included because these more recent procedures have been guided, in part, with thromboelastography (TEG), which is not applicable to most clinical practices. For inclusion, patients were initially identified by querying the electronic medical record for the pertinent diagnostic and procedural codes, and eligibility criteria were then confirmed via manual chart review. The diagnosis of cirrhosis was based on clinical, laboratory, imaging, and endoscopic findings, or histology where available. Those patients without a definite diagnosis of cirrhosis, those younger than 18 years of age, pregnant patients, postliver transplant patients, and those with acute gastrointestinal bleeding at the time of the procedure were excluded. Patients’ medical records were queried for bleeding events within 30 days from the time of the procedure and for mortality, within 90 days. The study was approved by the Indiana University Institutional Review Board.

**Outcomes**

The primary outcome was gastrointestinal bleeding (hematemesis, melena, hematochezia, and acute worsening anemia) within 30 days of the procedure (22) and was further divided into immediate and delayed bleedings. Immediate postpolypectomy bleeding was defined as bleeding occurring immediately after the polypectomy lasting more than 60 seconds, identified at the time of the procedure, and requiring hemostatic intervention (23). Delayed postpolypectomy bleeding was defined as bleeding occurring at the polypectomy site within 30 days of the procedure not meeting the above criteria for immediate bleeding. Secondary outcomes included mortality, blood transfusions, hospital admissions for gastrointestinal bleeding, and a requirement for repeat endoscopy, interventional radiology, or surgery.

**Variables**

Demographic and clinical information including age, sex, race, body mass index, comorbidities (Charlson comorbidity index) (24), presence of infection, and medication use (antiplatelet agents, anticoagulants, proton pump inhibitors, nonselective beta blockers, and nonsteroidal anti-inflammatory drugs [NSAIDs]) were collected. Liver disease-specific variables included cirrhosis etiology and liver disease severity (model for end-stage liver disease and Child-Pugh scores) (25,26). Laboratory values of interest included hemoglobin, platelet count, international normalized ratio (INR), and other markers of liver and kidney function (creatinine, sodium, blood urea nitrogen [BUN], albumin, and bilirubin). Fibrinogen was not available for most cases. Procedure-specific variables included patient location (inpatient vs outpatient), procedural indication (including cholangitis for ERCP (12), and use of prophylactic blood product transfusions. Other procedure-specific variables were examined separately depending on the procedure. For EVL, data included variate and presence of red wale signs, number of bands placed, and use of postprocedure proton pump inhibitor. For polypectomy, the number of polyps removed, largest polyp size, morphology and histology, polypectomy method, use of prophylactic endoscopic interventions to prevent bleeding (e.g., hemoclip), and the quality of the bowel preparation were recorded. For sphincterotomy, data collected included sphincterotomy length and the presence of periampullary diverticulum.

**Statistical analysis**

Continuous and categorical index patient characteristic data were summarized using 2 sample t tests for means and SDs and χ² tests for counts and percentages, respectively, with exact methods in the latter when sample size proved tenuous. Nonparametric tests of medians for continuous variables were used where required. Univariate and multivariable logistic regression models with an added random frailty at the patient level were used to account for patients with multiple procedures, incorporating only those variables significant at P < 0.05 in univariate analyses. Unadjusted and adjusted odds ratios and respective 95% confidence intervals (CIs) were reported. All analyses were performed using SAS 9.4.

**RESULTS**

After applying inclusion and exclusion criteria, the study sample included 1,324 procedures in 857 patients (886 upper endoscopies, 358 colonoscopies, and 80 ERCPs) (Figure 1).

**Esophageal variceal ligation**

Of 886 upper endoscopy procedures with esophageal variceal ligation (EVL) in 454 patients, postprocedural bleeding occurred after 25 procedures (2.8%) in 24 patients. Procedural indications were largely variceal screening and surveillance (96%). Active infection was present in 15 procedures—8 were spontaneous bacterial peritonitis and the remainder comprised bacteremia, pneumonia, Clostridioides difficile, cellulitis, and urinary tract infection. Patient characteristics at the time of their first procedure (N = 454) are shown in Table 1. Only the first procedure for each patient was included in this comparison to avoid double-counting characteristics in those with multiple procedures. A mean of 3.6 ± 1.5 bands were placed per endoscopy session. Five patients were taking NSAIDs, none of whom had bleeding. Among those taking antiplatelet agents, 26 were taking low-dose aspirin, 3 were taking clopidogrel, and 1 was taking both aspirin and clopidogrel. Patients who bled were younger, with lower hemoglobin and greater INR, BUN, bilirubin, MELD-Na score, and Child-Pugh score. Bleeding was also more common in
Bleeding occurred 12 ± 7 days postprocedure. Fifty percent presented with hematemesis, 27% with melena, 18% with hematochezia, and 5% with worsening anemia. Sixteen of 24 patients received pRBC transfusion (6.4 ± 7.6 units), 10 received platelet transfusion (1.7 ± 1.1 units), 11 received FFP (5.2 ± 3.7 units), and 4 received cryoprecipitate (2.8 ± 1.0 units). Ten patients required endoscopic intervention to control bleeding, and 1 patient required transjugular intrahepatic portosystemic shunt. Of the 24 patients who had postprocedure bleeding, 7 died in the 90-day follow-up period (29%). Three died from gastrointestinal bleeding with hemorrhagic shock, 2 died from sepsis, 1 from both bleeding and sepsis, and 1 from respiratory failure and cardiac arrhythmia.

**Colonscopy with polypectomy**

Of 358 procedures in 327 patients, there were 7 bleeding episodes (2.0%) in 7 patients. Colonoscopy indications were most often colorectal cancer screening (44%) and polyp surveillance (35%), with the remainder comprising liver transplant evaluation, lower gastrointestinal symptoms, and abnormal abdominal imaging. Patient characteristics at the time of their first procedure during the study period (N = 327) are shown in Table 3. There were 3.2 ± 2.6 polyps removed per colonoscopy (48% cold snare, 11% cold forceps, and 39% hot snare), with a maximum polyp size of 7.4 ± 6.5 mm, and prophylactic hemoclip was used in 14% of patients. Eight patients were taking NSAIDs, none of whom had bleeding. Patients who bled were younger, with lower hemoglobin and albumin, and greater INR, bilirubin, and MELD-Na and Child-Pugh scores. Platelet counts were not significantly different (mean 85 vs 117; \( P = 0.17 \)), although 29% of those who bled had a platelet count <50 × 10^3/mm^3 compared with 6.3% of those who did not bleed (\( P = 0.08 \)). Antiplatelet agents, anticoagulants, and polyp characteristics were not associated with bleeding. In particular, polyp size examined as both a continuous and as a categorical variable (≥1 vs <1 cm) was not associated with bleeding. Three patients received preprocedure prophylactic pRBC transfusion, 5 received prophylactic platelet transfusion, and 12 received FFP. Table 4 shows factors significantly associated with bleeding on univariate analysis across all 358 procedures. On univariate analysis, factors associated with bleeding included younger age, infection, inpatient location, lower hemoglobin, elevated INR, BUN, and MELD-Na and Child-Pugh scores. As both INR and liver disease severity have interdependent contributions to hemorrhage, 3 separate multivariable models were created, separately adjusting for (i) MELD-Na, (ii) Child-Pugh score, and (iii) the individual laboratory components. In all 3 multivariable models, bleeding was associated with younger age and lower hemoglobin. Bleeding was associated with infection in models adjusting for MELD-Na and Child-Pugh score, but not adjusting for individual laboratory values. Bleeding was associated with MELD-Na, but not with Child-Pugh score or with the individual laboratory results (including INR).

Bleeding occurred 12 ± 7 days postprocedure. Fifty percent presented with hematemesis and 2 patients presented with worsening anemia. All 7 warranted hospital admission; 5 bleeds stopped spontaneously without intervention, and 2 patients underwent successful endoscopic intervention. Five patients required pRBC transfusion (4.2 ± 3 units), 2 required platelet transfusion (6 ± 7 units), 2 required FFP (6 ± 4.2 units), and 1 patient required cryoprecipitate (3 units). One of 7 died during the 90-day follow-up period (unrelated to the bleeding).

**ERCP with sphincterotomy**

Eighty procedures were performed in 76 patients, with 3 episodes of post sphincterotomy bleeding (3.8%). ERCP was performed for choledocholithiasis in 45% and for biliary stricture in 14%. Cohort characteristics are shown in Table 5. Mean sphincterotomy hospitalization patients and in those with active infection. Bleeding was not associated with any of the examined medications, platelet count, or variceal characteristics. Preprocedure platelet transfusions were given to 23 patients. Twenty-three patients received prophylactic fresh frozen plasma (FFP), and 9 patients received packed red blood cell (pRBC) transfusions. Those who received pRBC transfusion were more likely to have postprocedure bleeding (odds ratio [OR] 10.61, 95% CI: 2.03–55.35), and FFP transfusion was also associated with postprocedural bleeding (OR 8.01, 95% CI: 2.57–24.94). Prophylactic platelet transfusion was not associated with bleeding.

Table 2 shows factors significantly associated with bleeding on univariate analysis across all 886 procedures. On univariate analysis, factors associated with bleeding included younger age, infection, inpatient location, lower hemoglobin, elevated INR, BUN, and MELD-Na and Child-Pugh scores. As both INR and liver disease severity have interdependent contributions to hemorrhage, 3 separate multivariable models were created, separately adjusting for (i) MELD-Na, (ii) Child-Pugh score, and (iii) the individual laboratory components. In all 3 multivariable models, bleeding was associated with younger age and lower hemoglobin. Bleeding was associated with infection in models adjusting for MELD-Na and Child-Pugh score, but not adjusting for individual laboratory values. Bleeding was associated with MELD-Na, but not with Child-Pugh score or with the individual laboratory results (including INR).

Bleeding occurred 12 ± 7 days postprocedure. Fifty percent presented with hematemesis and 2 patients presented with worsening anemia. All 7 warranted hospital admission; 5 bleeds stopped spontaneously without intervention, and 2 patients underwent successful endoscopic intervention. Five patients required pRBC transfusion (4.2 ± 3 units), 2 required platelet transfusion (6 ± 7 units), 2 required FFP (6 ± 4.2 units), and 1 patient required cryoprecipitate (3 units). One of 7 died during the 90-day follow-up period (unrelated to the bleeding).
length was 8.5 ± 1.6 mm, and 13% had a periampullary diverticulum. Six patients were on antiplatelet agents (all aspirin), and 1 patient who did not bleed was taking NSAIDs. Four patients received preprocedure platelet transfusions, and 10 received preprocedure FFP. None received postprocedural NSAIDs. Characteristics of the 3 patients who had a post sphincterotomy bleeding event are shown in Table 5. None of the 3 were outliers regarding any of the baseline characteristics, and none received either prophylactic FFP or platelet transfusions. One bleed was immediate, one occurred after 1 day, and the third occurred after 6 days. All 3 were hospitalized and were successfully treated endoscopically. None died within 90 days.

### Table 1. Patient characteristics according to the bleeding outcome at the index visit for endoscopic variceal ligation

|                  | Overall (N = 454) | No bleeding (N = 430) | Bleeding (N = 24) | P     |
|------------------|-------------------|-----------------------|-------------------|-------|
| Age (yr)         | 57.1 ± 11.1       | 57.5 ± 10.9           | 51.1 ± 12.7       | 0.02  |
| Female sex       | 176 (38.8)        | 172 (40)              | 4 (16.7)          | 0.11  |
| White race       | 416 (91.6)        | 401 (93.3)            | 15 (62.5)         | 0.07  |
| Cirrhosis etiology |                |                       |                   | 0.91  |
| Alcohol          | 81 (17.8)         | 78 (18.1)             | 3 (12.5)          |       |
| Alcohol/HCV      | 35 (7.7)          | 33 (7.7)              | 2 (8.3)           |       |
| Hepatitis C      | 118 (26.0)        | 112 (26.0)            | 6 (25.0)          |       |
| NASH             | 121 (26.7)        | 116 (27.0)            | 5 (20.8)          |       |
| Other            | 99 (21.8)         | 96 (22.3)             | 3 (12.5)          |       |
| Infection        | 11 (2.4)          | 7 (1.6)               | 4 (16.7)          | 0.001 |
| Charlson comorbidity index |         |                       |                   | 0.83  |
| 0–2              | 125 (27.5)        | 119 (27.7)            | 6 (25)            |       |
| 3–4              | 113 (24.9)        | 107 (24.9)            | 6 (25)            |       |
| 5–6              | 146 (32.2)        | 141 (32.8)            | 5 (20.8)          |       |
| >6               | 70 (15.4)         | 68 (15.8)             | 2 (8.3)           |       |
| Antiplatelet agents | 30 (6.6)         | 29 (6.7)              | 1 (4.2)           | 1     |
| Anticoagulation  | 8 (1.8)           | 7 (1.6)               | 1 (4.2)           | 0.29  |
| PPI              | 293 (64.5)        | 281 (65.3)            | 12 (50)           | 0.90  |
| Beta-blocker     | 196 (43.2)        | 188 (43.7)            | 8 (33.3)          | 0.92  |
| Hemoglobin (g/dL)| 11.7 ± 2.2        | 11.8 ± 2.2            | 10.3 ± 1.7        | 0.004 |
| Platelets (10^3/mm^3)| 98.6 ± 59.9      | 98.6 ± 60.2           | 98.3 ± 56.1       | 0.98  |
| INR              | 1.3 ± 0.3         | 1.3 ± 0.3             | 1.6 ± 0.6         | <0.0001|
| Creatinine (mg/dL)| 1.0 ± 0.7         | 0.9 ± 0.7             | 1.2 ± 0.8         | 0.15  |
| Sodium (mmol/L)  | 136.3 ± 3.9       | 136.4 ± 3.9           | 134.7 ± 3.9       | 0.08  |
| BUN (mg/dL)      | 15.2 ± 11.2       | 14.9 ± 10.7           | 21.3 ± 18.5       | 0.02  |
| Albumin (g/dL)   | 3.3 ± 0.6         | 3.2 ± 0.6             | 3.5 ± 0.8         | 0.14  |
| Bilirubin (mg/dL)| 2.0 ± 2.3         | 1.9 ± 2.1             | 4.7 ± 4.2         | <0.0001|
| MELD-Na          | 14.9 ± 5.5        | 14.6 ± 5.3            | 20.9 ± 7.7        | <0.0001|
| Child-Pugh score | 7.6 ± 1.9         | 7.5 ± 1.9             | 8.5 ± 2.3         | 0.03  |
| Inpatient location| 38 (8.4)          | 33 (7.7)              | 5 (20.8)          | 0.01  |
| Large varices    | 437 (96.3)        | 418 (97.2)            | 19 (79.2)         | 0.37  |
| No. of bands     | 3.6 ± 1.5         | 3.6 ± 1.5             | 3.9 ± 1.6         | 0.34  |
| Red wale signs   | 104 (24.7)        | 100 (23.3)            | 4 (16.7)          | 1     |
| Postprocedure PPI| 316 (72.3)        | 303 (70.5)            | 13 (54.2)         | 0.69  |

Values expressed as n (%) or mean ± SD. P value comparisons across outcome categories are based on the χ² tests (or Fisher exact test) for categorical variables; P values for continuous variables are based on ANOVA or Wilcoxon (Normal Approximation).

Only the first (index) procedure during the study period was included in this comparison to avoid double counting patients. BUN, blood urea nitrogen; HCV, hepatitis C virus; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PPI, proton pump inhibitor.
DISCUSSION

This study of 1,324 endoscopic interventions in 857 patients is the largest to date examining postendoscopy bleeding in patients with cirrhosis. Three commonly performed endoscopic interventions associated with a high risk of bleeding (EVL, polypectomy, and sphincterotomy) were examined (6), with a relatively low post-procedural bleeding rate (2%–4%) across procedures despite frequent thrombocytopenia and prolonged INR. For both EVL and polypectomy, postprocedural bleeding was associated with several measures of liver disease severity, notably elevated INR, as well as younger age, lower hemoglobin, active infection, and inpatient location. Importantly, bleeding was not associated with platelet count. In those who experienced bleeding, short-term mortality was high, particularly in those who bled after EVL.

The observed postpolypectomy bleed rate of 2% is similar to other studies of cirrhosis (8–10,27), and greater than rates in the general population (0.2%–0.6%) (22,28), reinforcing the importance of this topic in cirrhosis clinical care. EVL was also associated with bleeding in 2.8%, consistent with previous work showing rates of 2%–8% (7,15–18,29). In both procedures, bleeding was associated with elevated INR in univariate analysis, but not in multivariable analysis, and in neither procedure was bleeding associated with platelet count. The lack of association between standard hemostasis measures and postprocedural bleeding highlights the evolving notion that these measures do not adequately capture the complex nature of hemostasis and coagulopathy in patients with liver disease (1). This lack of association with platelet count also has particular clinical relevance because providers are often reluctant to perform procedures in patients with thrombocytopenia, and several new thrombopoietin agonists have been developed for this purpose. Notably, despite the improvement in platelet counts seen with these agents, more robust outcomes data are needed to establish their efficacy in reducing bleeding (30). These findings suggest that provider perceptions of bleeding risk due to thrombocytopenia may be disproportionate to the actual risk. The limitations of standard measures of hemostasis have prompted several studies of viscoelastic testing, such as TEG, as a more global, functional approach to assessing bleeding risk. Indeed, promising studies have suggested the potential for TEG to reduce blood product use in this population without sacrificing bleeding risk (31,32).

Bleeding after both EVL and polypectomy was independently associated with both younger age and lower hemoglobin. Younger age, although not a traditional risk factor for postendoscopy bleeding, has been noted to be numerically lower in those with bleeding in some studies (8,16–19). Interestingly, several studies have documented increased procoagulant profiles with advancing age (33,34), explaining in part the increased incidence of thrombotic disorders in older individuals. Whether the relative lack of procoagulant factors in liver disease is amplified in younger patients remains to be seen and deserves further study. The relationship between bleeding and low hemoglobin is also novel. Although low hemoglobin has not been associated with postendoscopy bleeding in previous studies, it is associated with an increased risk of major bleeding in patients with acute coronary syndrome (35). Purported mechanisms for this finding include reduced blood viscosity, shear stress, and platelet activation (36). Whether careful correction of anemia with PRBC transfusion might reduce bleeding risk is unclear; there was increased post-EVL bleeding in those who received PRBC transfusion, a finding that may reflect the increased bleeding risk associated with the underlying anemia. Furthermore, in univariate analysis,
|                                    | Overall (N = 327) | No bleeding (N = 320) | Bleeding (N = 7) | P     |
|------------------------------------|------------------|----------------------|-----------------|-------|
| Age (yr)                           | 59.6 ± 8.6       | 59.8 ± 8.5           | 52.0 ± 11.4     | 0.01  |
| Female sex                         | 138 (42.2)       | 134 (41.9)           | 4 (57.1)        | 0.46  |
| White race                         | 292 (89.3)       | 285 (89.1)           | 7 (100.0)       | 0.35  |
| Cirrhosis etiology                 |                  |                      |                 | 0.06  |
| Alcohol                            | 76 (23.2)        | 74 (23.1)            | 2 (28.6)        |       |
| Alcohol/HCV                        | 31 (9.5)         | 28 (8.8)             | 3 (42.9)        |       |
| Hepatitis C                        | 78 (23.9)        | 77 (24.1)            | 1 (14.3)        |       |
| NASH                               | 73 (22.3)        | 72 (22.5)            | 1 (14.3)        |       |
| Other                              | 69 (21.1)        | 69 (21.6)            | 0               |       |
| Infection                          | 10 (3.1)         | 9 (2.8)              | 1 (14.3)        | 0.19  |
| Charlson comorbidity index         |                  |                      |                 | 0.77  |
| 0–2                                | 85 (26.0)        | 83 (25.9)            | 2 (28.6)        |       |
| 3–4                                | 85 (26.0)        | 84 (26.3)            | 1 (14.3)        |       |
| 5–6                                | 106 (32.4)       | 104 (32.5)           | 2 (28.6)        |       |
| >6                                 | 51 (15.6)        | 49 (15.3)            | 2 (28.6)        |       |
| Antiplatelet agents                | 43 (13.1)        | 42 (13.1)            | 1 (14.3)        | 1     |
| Anticoagulation                    | 15 (4.6)         | 14 (4.4)             | 1 (14.3)        | 0.28  |
| Hemoglobin (g/dL)                  | 12.4 ± 2.2       | 12.5 ± 2.2           | 9.5 ± 2.3       | <0.001|
| Platelets (10^9/mm³)               | 116.1 ± 61.0     | 116.8 ± 61.2         | 85.1 ± 43.6     | 0.17  |
| INR                                | 1.3 ± 0.3        | 1.3 ± 0.2            | 1.7 ± 0.5       | 0.001 |
| Creatinine (mg/dL)                 | 1.1 ± 1.1        | 1.1 ± 1.1            | 1.1 ± 0.8       | 0.93  |
| Sodium (mmol/L)                    | 136.6 ± 3.6      | 136.5 ± 3.6          | 137.7 ± 3.2     | 0.42  |
| BUN (mg/dL)                        | 15.5 ± 12.6      | 15.7 ± 12.7          | 9.7 ± 5.9       | 0.21  |
| Albumin (g/dL)                     | 3.4 ± 0.6        | 3.4 ± 0.6            | 2.8 ± 0.5       | 0.01  |
| Bilirubin (mg/dL)                  | 1.9 ± 2.6        | 1.8 ± 1.8            | 7.5 ± 12.7      | <0.0001|
| MELD-Na                            | 15 ± 5.8         | 14.9 ± 5.7           | 19.5 ± 7.4      | 0.03  |
| Child-Pugh score                   | 7.6 ± 2.1        | 7.5 ± 2.1            | 9.8 ± 3.0       | 0.005 |
| Inpatient location                 | 29 (8.9)         | 24 (7.5)             | 5 (71.4)        | <0.0001|
| No. of polyps                      | 3.2 ± 2.6        | 3.2 ± 2.6            | 2.8 ± 1.7       | 0.67  |
| Largest polyp size (mm)            | 7.4 ± 6.5        | 7.4 ± 6.5            | 9.4 ± 7.3       | 0.41  |
| Morphology (largest)               |                  |                      |                 | 0.63  |
| Flat                               | 13 (4.4)         | 13 (4.5)             | 0               |       |
| Pedunculated                       | 26 (8.1)         | 25 (8.6)             | 1 (14.3)        |       |
| Sessile                            | 258 (86.9)       | 252 (86.9)           | 6 (85.7)        |       |
| Technique (largest)                |                  |                      |                 | 1     |
| Cold forceps                       | 34 (10.5)        | 34 (10.7)            | 0               |       |
| Cold snare                         | 156 (48.0)       | 152 (47.8)           | 4 (57.1)        |       |
| Hot snare                          | 126 (38.8)       | 123 (38.7)           | 3 (42.9)        |       |
| Other                              | 9 (2.8)          | 9 (2.8)              | 0               |       |
| Prophylactic hemoclip              | 46 (14.1)        | 45 (14.1)            | 1 (14.3)        | 1     |

Values expressed as n (%) or mean ± SD.
P-value comparisons across outcome categories are based on χ² tests (or Fisher exact tests) for categorical variables; P-values for continuous variables are based on ANOVA or Wilcoxon (Normal Approximation).
Only the first (index) procedure during the study period was included in this comparison to avoid double counting patients.
BUN, blood urea nitrogen; HCV, hepatitis C virus; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PPI, proton pump inhibitor.
Table 4. Predictors of bleeding in patients after polypectomy

| Variable       | Unadjusteda | Adjusted (MELD-Na)b | Adjusted (Child-Pugh)b | Adjusted (individual labs)b |
|----------------|-------------|---------------------|------------------------|-----------------------------|
| Age            | 0.90 (0.83–0.99), 0.02 | 0.92 (0.86–0.98), 0.001 | 0.92 (0.85–0.99), 0.03 | 0.92 (0.85–0.99), 0.04 |
| Hemoglobin     | 0.56 (0.37–0.83), 0.004 | 0.59 (0.41–0.84), 0.04 | 0.63 (0.47–0.84), 0.002 | 0.66 (0.45–0.98), 0.04 |
| INR            | 8.45 (2.31–30.87), 0.001 | 1.66 (0.31–8.90), 0.55 | 1.05 (0.96–1.16), 0.28 | |
| Albumin        | 0.26 (0.11–0.61), 0.002 | 0.39 (0.13–1.16), 0.09 | 0.36 (0.11–1.20), 0.10 | |
| Bilirubin      | 1.11 (1.03–1.19), 0.006 | 0.99 (0.91–1.08), 0.82 | 1.16 (0.83–1.64), 0.39 | |
| MELD-Na        | 1.09 (1.01–1.18), 0.04 | 1.05 (0.96–1.16), 0.28 | |
| Child-Pugh     | 1.52 (1.05–2.19), 0.03 | 1.16 (0.83–1.64), 0.39 | |
| Inpatient      | 30.00 (5.52–163.15), <0.001 | |

All values displayed as odds ratio (95% confidence interval), P value.
INR, international normalized ratio; MELD, Model for End-Stage Liver Disease.
*aWithin-subject cluster-adjusted univariate odds ratio.
*bWithin-subject cluster-adjusted multivariable odds ratio using continuous scores to increase degrees of freedom.

Elevated INR was also associated with bleeding, potentially accounting for the increased bleeding in those who received pre-procedure FFP transfusions. For both pRBC and FFP transfusions, previous studies have demonstrated transfusion-induced increased portal pressure that could also result in increased bleeding (37,38).

In univariate analysis, inpatient location was associated with bleeding after EVL and polypectomy, and in multivariable analysis, active infection (despite appropriate treatment) was associated with post-EVL bleeding. Hospitalized patients with cirrhosis frequently have coexisting acute medical issues such as acute-on-chronic liver failure or infection, which can increase the risk of bleeding. These findings suggest that elective endoscopic interventions (particularly polypectomy) in this population may not be appropriate for hospitalized patients and may best be deferred to the outpatient setting. These data confirming the increased risk in the setting of infection are consistent with other work showing impaired hemostasis in liver disease resulting from increased circulating endogenous heparinoids (39–41). This increased risk remains substantial despite appropriate antibiotic therapy and suggests that elective endoscopic procedures should wait until infection has been eradicated whenever possible.

This study is the largest detailed examination of bleeding after commonly performed interventional endoscopic procedures in patients with cirrhosis. In contrast to previous work, this study excluded patients with active bleeding and included patients, regardless of the severity of their liver disease or their use of antiplatelet agents and anticoagulants. Thus, this sample best reflects the population in which evidence-based decisions can be made regarding procedural timing and medication continuation or discontinuation. The novel findings of increased bleeding risk in younger patients and in those with lower hemoglobin need further validation and investigation to determine whether prophylactic interventions might be able to further lower the risk for bleeding. In contrast to these strengths, this study has some weaknesses, including its retrospective design and the low number of bleeding events, which limited the ability to examine risk factors, particularly for those undergoing ERCP with sphincterotomy. The low number of bleeding events also prevents the development of a prediction model from these data that could more accurately stratify bleeding risk in this population.

Although the procedures occurred several years ago, this time frame was necessary to avoid the confounding impact of TEG, which has been used at this center in the past several years to help stratify bleeding risk. TEG is not readily available for this purpose in most hospitals in the United States and thus including procedures where TEG was considered would not be widely applicable.

Although uncommon, bleeding after therapeutic endoscopy in patients with cirrhosis is associated with significant morbidity and mortality. Knowledge of underlying risk factors, including younger age, lower hemoglobin, greater liver disease severity, and infection may help providers best determine the appropriate timing and preprocedural management of patients to optimize outcomes. Careful collection of these relevant factors can be used to optimize the environment and mitigate potential risks to the greatest extent possible with a goal of preventing postprocedural bleeding. Caution in interpreting standard measures of hemostasis (INR and platelet count) is warranted as well to avoid unnecessary prophylactic blood product transfusions. Future prospective research focused on correcting modifiable risk factors is needed to understand whether bleeding can be further reduced in this population.

CONFLICTS OF INTEREST
Guarantor of the article: Eric S. Orman, MD, MSCR.
Specific author contributions: Shanker Kundumadam, MBBS, and Parkpoom Phatharacharukul, MD, shared first authorship. S.K.: data collection, analysis and interpretation, drafting, and article revision. P.P.: conception and design, data collection, and data analysis. K.R. and A.Y.: data collection and data analysis. H.S.: data collection and data analysis and interpretation. F.P.: data analysis and interpretation and drafting the article. N.C.: conception and design, article revision, and article approval. K.R.P. and M.G.: article revision and article approval. E.S.O.: conception and design, data analysis and interpretation, drafting, revision, and article approval. All authors have approved the final draft.
Financial support: Research reported in this publication was supported, in part, by the National Institutes of Health under award number K23DK109202. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Table 5. Characteristics of patients undergoing ERCP with sphincterotomy

| Overall (N = 80) | Patient 1 | Patient 2 | Patient 3 |
|------------------|-----------|-----------|-----------|
| Age (yr) 56.3 ± 13.8 | 59 | 62 | 71 |
| Female sex 35 (43.8) | F | F | M |
| White race 75 (93.8) | Black | White | White |
| Cirrhosis etiology | HCV | Alcohol | Alcohol |
| Alcohol 20 (25.0) | | | |
| Alcohol/HCV 11 (13.8) | | | |
| Hepatitis C 10 (12.5) | | | |
| NASH 15 (18.8) | | | |
| Other 24 (30.0) | | | |
| Infection 4 (5.0) | No | No | Yes |
| Charlson comorbidity index | 5 | 3 | 10 |
| 0–2 | 21 (26.3) | | |
| 3–4 | 27 (33.8) | | |
| 5–6 | 20 (25.0) | | |
| >6 | 12 (15.0) | | |
| Antiplatelet agents | None | None | Aspirin |
| Anticoagulation | 6 (7.5) | | |
| 0.9 ± 0.4 | 1.0 | 0.6 | 0.6 |
| Sodium (mM/L) 136.7 ± 4.2 | 137 | 134 | 131 |
| BUN (mg/dL) 14.0 ± 10.2 | 12 | 5 | 7 |
| Albumin (g/dL) 3.2 ± 0.8 | 3.2 | 3.6 | 1.8 |
| Bilirubin (mg/dL) 4.1 ± 5.3 | 0.8 | 1.3 | 0.5 |
| MELD-Na 16.2 ± 6.3 | 10 | 15 | 18 |
| Child-Pugh score 7.9 ± 2.3 | 6 (A) | 8 (B) | 7 (B) |
| Inpatient location 38 (47.5) | Out | In | Out |
| Sphincterotomy length (mm) 8.5 ± 1.9 | 10 | 10 | 8 |
| Periampullary diverticulum 10 (12.7) | No | Yes | No |
| Timing of bleed (d) 1 Immediate | 6 | |

BUN, blood urea nitrogen; ERCP, endoscopic retrograde cholangiopancreatography; HCV, hepatitis C virus; INR, international normalized ratio; MELD, Model for End-Stage Liver Disease; NASH, nonalcoholic steatohepatitis; PPI, proton pump inhibitor.

Potential competing interests: N. Chalasani: paid consultation with the following companies: AbbVie, Allergan, Madrigal, La Jolla, Foresite Labs, Axcella, Zydis, and Galectin; research grants with the following companies: Exact Sciences, DSM, and Intercept. All other authors disclosed that they have no declared conflicts of interests.

Study Highlights

**WHAT IS KNOWN**

- Hemostatic and coagulation abnormalities in cirrhotic patients could potentially increase the risk of bleeding after invasive procedures.

**WHAT IS NEW HERE**

- Risk factors of bleeding in cirrhotic patients after endoscopic procedures were studied.
- This study is the largest detailed examination of bleeding after commonly interventional endoscopic procedures.
- Low preprocedure hemoglobin and younger age were consistently associated with postprocedural bleeding.
- Platelet count and International normalized ratio (INR) did not have a significant association with postprocedural bleeding.

**TRANSLATIONAL IMPACT**

- These characteristics may be used to help stratify bleeding risk in future practice.

**REFERENCES**

1. Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011;365(2):147–56.
2. Shah NL, Northup PG, Caldwell SH. A clinical survey of bleeding, thrombosis, and blood product use in decompensated cirrhosis patients. Ann Hepatol 2012;11(5):686–90.
3. Seeff LB, Everson GT, Morgan TR, et al. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol 2010;8(10):877–83.
4. Kovalak M, Lake J, Matté N, et al. Endoscopic screening for varices in cirrhotic patients: Data from a national endoscopic database. Gastrointest Endosc 2007;65(1):82–8.
5. Naveau S, Chapnutt JC, Redossa P, et al. Cirrhosis as an independent risk factor for colon adenomas. Gut 1992;33(4):535–40.
6. Acosta RD, Abraham NS, Chandrasekharra V, et al. The management of antithrombotic agents for patients undergoing GI endoscopy. Gastrointest Endosc 2016;83(1):3–16.
7. Vieira da Rocha EC, D’Amico EA, Caldwell SH, et al. A prospective study of conventional and expanded coagulation indices in predicting ulcer bleeding after variceal band ligation. Clin Gastroenterol Hepatol 2009;7(9):988–93.
8. Jeon JW, Shin HP, Lee JI, et al. The risk of postpolypectomy bleeding during colonoscopy in patients with early liver cirrhosis. Surg Endosc 2012;26(11):3258–63.
9. Lee HS, Park JJ, Kim SU, et al. Incidence and risk factors of delayed postpolypectomy bleeding in patients with chronic liver disease. Scand J Gastroenterol 2016;51(5):618–24.
10. Lee S, Park SJ, Cheon JH, et al. Child-Pugh score is an independent risk factor for immediate bleeding after colonoscopic polypectomy in liver cirrhosis. Yonsei Med J 2014;55(3):1281–8.
11. Zhang J, Ye L, Zhang J, et al. MELD scores and Child-Pugh classifications predict the outcomes of ERCP in cirrhotic patients with choledocholithiasis: A retrospective cohort study. Medicine (Baltimore) 2015;94(3):e433.
12. Freeman ML, Nelson DB, Sherman S, et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335(13):909–19.
13. Adler DG, Haseeb A, Francis G, et al. Efficacy and safety of therapeutic ERCP in patients with cirrhosis: A large multicenter study. Gastrointest Endosc 2016;83(2):353–9.

14. Navaneethan U, Njei B, Zhu X, et al. Safety of ERCP in patients with liver cirrhosis: A national database study. Endosc Int Open 2017;5(4):E303–14.

15. Duches E, Cacherio A, Amador A, et al. Ulcer bleeding after band ligation of oesophageal varices: Risk factors and prognosis. Dig Liver Dis 2020;52(1):79–83.

16. Cho E, Jun CH, Cho SB, et al. Endoscopic variceal ligation–induced ulcer bleeding: What are the risk factors and treatment strategies? Medicine (Baltimore) 2017;96(24):1–6.

17. Tierney A, Toriz BE, Mian S, et al. Interventions and outcomes of treatment of postbanding ulcer hemorrhage after endoscopic band ligation: A single-center case series. Gastrointest Endosc 2015;77(1):136–40.e1.

18. Vanhrievliet G, Giudicelli-Bornard S, Piche T, et al. Predictive factors of bleeding related to post-banding ulcer following endoscopic variceal ligation in cirrhotic patients: A case control study. Aliment Pharmacol Ther 2010;32(2):225–32.

19. Li J, Han B, Li H, et al. Association of coagulopathy with the risk of bleeding after invasive procedures in liver cirrhosis. Saudi J Gastroenterol 2018;24(4):220–7.

20. Giannini EG, Greco A, Marenco S, et al. Incidence of bleeding following invasive procedures in patients with thrombocytopenia and advanced liver disease. Clin Gastroenterol Hepatol 2010;8(10):899–902.

21. Napolitano G, Iacobellis A, Merla A, et al. Bleeding after invasive procedures is rare and unpredicted by platelet counts in cirrhotic patients with thrombocytopenia. Eur J Intern Med 2017;38:79–82.

22. Rabeneck L, Paszat LF, Hilsden RJ, et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008;135(6):1899–906, 1906.e1.

23. Kim HS, Kim TJ, Kim WH, et al. Risk factors for immediate postpolypectomy bleeding of the colon: A multicenter study. Am J Gastroenterol 2006;101(6):1333–41.

24. Charlooen ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis 1987;40(5):373–83.

25. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60(8):646–9.

26. Organ Procurement and Transplantation Network Policies. (https://optn.transplant.hrsa.gov/media/1200/optn_policies.pdf). Published 2020. Accessed June 28, 2020.

27. Huang R, Perumpail R, Thosani N, et al. Colonoscopy with polypectomy is associated with a low rate of complications in patients with cirrhosis. Endosc Int Open 2016;4(9):E947–52.

28. Rutter MD, Nickerson C, Rees CJ, et al. Risk factors for adverse events related to polypectomy in the English Bowel Cancer Screening Programme. Endoscopy 2014;46(2):90–7.

29. Shaheen NJ, Stuart E, Schmitz SM, et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: A randomized, controlled trial. Hepatology 2005;41(3):588–94.

30. Nilles KM, Caldwell SH, Flamm SL. Thrombocytopenia and procedural prophylaxis in the era of thrombopoitin receptor agonists. Hepat Commun 2019;3(11):1423–34.

31. De Pietri I, Bianchini M, Montalti R, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016;63(2):566–73.

32. Rout G, Shalimar, Gunjan D, et al. Thrombelastography-guided blood product transfusion in cirrhosis patients with variceal bleeding: A randomized controlled trial. J Clin Gastroenterol 2020;54(3):255–62.

33. Conlan MG, Folsoom AR, Finch A, et al. Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study. Thromb Haemost 1993;70(3):380–5.

34. Sepúlveda C, Palomo I, Fuentes E. Primary and secondary haemostasis changes related to aging. Mech Ageing Dev 2015;150:46–54.

35. Bassand J-P, Afzal R, Eikelboom J, et al. Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. Eur Heart J 2009;31(1):50–8.

36. Eugster M, Reinhart WH. The influence of the haematocrit on primary haemostasis in vitro. Thromb Haemost 2005;94(6):1213–8.

37. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013;368(1):11–21.

38. Castañeda B, Morales J, Lionetti R, et al. Effects of blood volume restitution following a portal hypertensive-related bleeding in anesthetized cirrhotic rats. Hepatology 2001;33(4):821–5.

39. Shamsedddeen H, Patidar KR, Ghabril M, et al. Features of blood clotting on thromboelastography in hospitalized patients with cirrhosis. Am J Med 2020;133(12):1479–87.e2.

40. Papafilesoridis GV, Patch D, Webster GJ, et al. Infection and hemostasis in decompensated cirrhosis: A prospective study using thromboelastography. Hepatology 1999;29(4):1085–90.

41. Senzolo M, Riddell A, Tuddenham E, et al. Endogenous heparinoids contribute to coagulopathy in patients with liver disease. J Hepatol 2008;48(2):371–3.

---

Open Access: This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.